Core Viewpoint - The approval of the inhaled powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant milestone for the company, allowing it to proceed with clinical trials for idiopathic pulmonary fibrosis and potentially other related conditions [1] Group 1: Product Development - The inhaled formulation of Nintedanib has received approval for clinical trials in China, specifically targeting idiopathic pulmonary fibrosis [1] - The product also shows potential for treating systemic sclerosis-related interstitial lung disease and progressive pulmonary fibrosis [1] - This approval is considered a key achievement for the company's inhalation technology platform, laying a solid foundation for the development of subsequent inhalation formulations [1] Group 2: Market Reaction - Following the announcement, the company's stock price increased by 4.13%, reaching HKD 8.83, with a trading volume of HKD 1.153 billion [1]
石药集团涨超4% 乙磺酸尼达尼布吸入粉雾剂获批临床